---
title: "Cardinal Health Lifts FY26 Adj. Earnings View Above Market"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/272409872.md"
description: "Cardinal Health Inc. (CAH) has raised its fiscal 2026 adjusted earnings outlook to at least $10.00 per share, up from the previous range of $9.65 to $9.85, due to strong performance across its five operating segments. The company's shares rose by 1.3% in pre-market trading. Cardinal Health also projects Specialty revenues to exceed $50 billion in fiscal 2026, driven by robust demand and significant growth in BioPharma Solutions. Further details will be provided during the second quarter earnings call on February 5."
datetime: "2026-01-13T12:17:12.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/272409872.md)
  - [en](https://longbridge.com/en/news/272409872.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/272409872.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/272409872.md) | [繁體中文](https://longbridge.com/zh-HK/news/272409872.md)


# Cardinal Health Lifts FY26 Adj. Earnings View Above Market

Add  as your preferred news source on Google

 Add Now

Cardinal Health Inc. (CAH), a distributor of pharmaceuticals and specialty products, on Tuesday lifted its fiscal 2026 adjusted earnings outlook again, driven by strong performance and execution across its five operating segments.

In pre-market activity, the shares were gaining around 1.3 percent, trading at $205.01.

Jason Hollar, CEO of Cardinal Health, stated, "Our team's execution against our strategic growth plan continues to deliver meaningful results, and as a demonstration of our confidence and momentum, we are pleased to again raise our expectations for fiscal year 2026."

For fiscal 2026, Cardinal Health now expects adjusted earnings per share of at least $10.00, higher than its prior guidance range of $9.65 to $9.85.

The Wall Street analysts on average expect the company to report earnings of $9.83 per share for the year. Analysts' estimates typically exclude special items.

Further, the company projects that its Specialty revenues will surpass $50 billion in fiscal 2026, marking a 16 percent compounded annual growth rate or CAGR over three years. According to the firm, robust demand across specialty distribution, the expansion of its MSO platforms and over 30 percent anticipated revenue growth in BioPharma Solutions in fiscal 2026 will benefit the revenue growth.

The firm said it plans to highlight significant progress with its strategic growth initiatives during the 44th Annual J.P. Morgan Healthcare Conference.

In addition, Cardinal Health confirmed the transition of its manufacturer distribution service agreements for all branded pharmaceutical products impacted by the 2026 Medicare Drug Price Negotiation Program.

The company is scheduled to provide further details and updates on its upcoming second quarter earnings call on February 5.

For comments and feedback contact: editorial@rttnews.com

Business News

### Related Stocks

- [Cardinal Health, Inc. (CAH.US)](https://longbridge.com/en/quote/CAH.US.md)

## Related News & Research

- [Endeavour To Announce Its Q1 2026 Results On 30 April 2026 | EDVMF Stock News](https://longbridge.com/en/news/281490237.md)
- [General Dynamics' Q1 2026 Earnings: What to Expect](https://longbridge.com/en/news/281006069.md)
- [Shanghai Fudan-Zhangjiang Bio-Pharmaceutical subscribes to structured deposit product under Bank of China](https://longbridge.com/en/news/281521127.md)
- [SILICOM'S FIRST QUARTER 2026 RESULTS RELEASE SCHEDULED FOR APRIL 30, 2026 | SILC Stock News](https://longbridge.com/en/news/281187073.md)
- [Allegion's Q1 2026 Earnings: What to Expect](https://longbridge.com/en/news/281189148.md)